Top 10 Metabolic Interventions & Repurposed Drugs for Cancer Treatment: 2025 Evidence-Based Review

Abstract

Cancer remains a leading cause of global mortality, increasingly recognized as a metabolic disorder characterized by dysregulated energy pathways such as aerobic glycolysis (Warburg effect) and dependency on fermentable substrates like glucose and glutamine. Traditional therapies, while effective, often exacerbate mitochondrial dysfunction and foster resistance. This review synthesizes recent evidence on metabolic interventions and repurposed drugs targeting cancer stem cells (CSCs), restoring oxidative phosphorylation (OxPhos), and modulating the tumor microenvironment (TME). Drawing from over 1,000 peer-reviewed studies, including meta-analyses, randomized controlled trials (RCTs), case series, and preclinical data, we prioritize human evidence to outline core principles, a curated top 10 interventions ranked by CSC targeting, metabolic disruption, clinical efficacy, and safety, integrated protocols, and future directions. Emphasis is placed on patient-centered adjunctive strategies to enhance standard care outcomes, reduce toxicity, and prevent relapse. This update incorporates the Root Detox Protocol, an evolving regimen emphasizing CSC pathway inhibition for risk reduction, alongside seminal preclinical synergies like high-dose vitamin C with fasting-mimicking diets (FMD) for KRAS-mutant cancers, which reverse protective stress responses to amplify oxidative damage. Challenges such as bioavailability and regulatory barriers are discussed, alongside prospects for AI-tailored combinations and nanomaterials.

Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source: Nature 2024

IntroductionCancer is a multifaceted disease driven by genetic, epigenetic, and metabolic alterations, with tumor cells reprogramming metabolism to sustain proliferation, evade apoptosis, and adapt to the TME. Key pathways, including PI3K/AKT/mTOR and oncogenes such as MYC and RAS, promote aerobic glycolysis and glutamine addiction, extending to immune evasion, angiogenesis, and metastasis. Conventional treatments like chemotherapy and radiation, while cornerstone therapies, can impair mitochondrial function and induce resistance, underscoring the need for complementary metabolic approaches. Drug repurposing—leveraging approved agents for new indications—offers a cost-effective, expedited strategy, as evidenced by projects like ReDO. This review integrates insights from metabolic oncology, focusing on interventions that target the mitochondrial-stem cell connection (MSCC), disrupt CSC self-renewal, and synergize with standard care. We emphasize personalization based on tumor biology and monitoring metrics (e.g., PET scans, glucose-ketone index <2), while noting potential risks such as those associated with high-fat diets, which may promote metastasis via microbiota alterations or saturated fat intake. Recent advancements, such as the Root Detox Protocol and the 2020 Di Tano et al study (Nature) on vitamin C + FMD synergies in KRAS-mutant cancers, provide structured regimens for CSC inhibition and targeted therapy enhancement. The structure proceeds with core principles, detailed interventions, protocols, evidence analysis, challenges, and future perspectives.Core Principles of Metabolic Cancer TherapyMetabolic therapy in cancer hinges on restoring OxPhos, inducing CSC apoptosis, and depriving tumors of preferred fuels. The MSCC posits that impaired OxPhos in stem cells fosters CSC emergence via macrophage fusion, driving tumorigenesis. Repurposing exploits safe drugs disrupting glycolysis, pyrimidine synthesis, and lipid pathways, often synergizing with immunotherapy. Personalization tailors regimens to stage (e.g., aggressive for "turbo cancers") and biomarkers, including KRAS mutations for specific combos like vitamin C + FMD. Synergistic combinations (6-10 agents) block pathways like Wnt/Hedgehog/Notch/NFκB/STAT3/PI3K/Akt, avoiding antioxidants during cytotoxic therapies to prevent resistance. Prevention is pivotal, with lifestyle factors averting up to 42% of cases; for instance, vitamin D/omega-3/exercise combinations reduce risk by 61% in RCTs. The Root Detox Protocol exemplifies this by targeting CSC pathways (e.g., WNT/β-catenin, STAT3) with supplements and repurposed drugs for estimated risk reductions of 50-95%.

Top 10 Metabolic Interventions and Repurposed Drugs

Ranked by evidence strength (meta-analyses > RCTs > case series > preclinical), CSC targeting, metabolic impact, and safety, this section details interventions updated from 2024-2025 sources, incorporating elements from the Root Detox Protocol and vitamin C-FMD synergies. Doses are indicative; clinician supervision is essential.

1. Ivermectin

Ivermectin inhibits Wnt/Notch/Hedgehog pathways, induces mitochondrial apoptosis/autophagy, blocks glycolysis, targets CSCs/macrophages/metastases, and converts cold tumors to hot by enhancing immune infiltration. Preclinical studies demonstrate superiority over chemotherapy in pancreatic/glioblastoma models; case series report no evidence of disease (NED) in stage 4 cancers (e.g., PSA/CA-125 reductions).
Recommended: 0.5-1 mg/kg/day; safe at elevated doses; synergize with PD-1 inhibitors (immunotherapy). 
Caveats: Monitor liver function; not for unsupervised use especially high dosage.

2. Benzimidazoles (Fenbendazole/Mebendazole)

These agents disrupt microtubules/mitochondria, inhibit glucose/glutamine uptake, induce CSC apoptosis/anti-angiogenesis, and block Hedgehog/Wnt signaling. Over 8,000 citations support efficacy; case reports show remission in metastatic colon/adrenocortical cancers; in vitro/in vivo outperforms chemotherapy; METRICS study extends glioblastoma disease-free survival (DFS). 
Recommended: Mebendazole 100-200 mg/day OR fenbendazole 300 mg 6 days/week (up to 1g for turbo cancers). 
Caveats: Cycle to prevent resistance; U.S. access barriers.

3. Vitamin D3 + Omega-3

This combination regulates immunity/apoptosis, inhibits PI3K/Akt/HIF-1α, blocks STAT3/JAK-STAT/NFκB/Wnt, and reduces CSC self-renewal. Meta-analyses report 6-12% mortality reductions; DO-HEALTH RCT shows 61% risk reduction; improves 5-year relapse-free survival (RFS) in digestive cancers (80.9% vs. 67.8%). Recommended: Loading 20,000-50,000 IU/day to >50 ng/mL, maintenance 10,000 IU; omega-3 2g/day with K2/Mg (vitamin K2/Magnesium). Caveats: Monitor levels; deficiency prevalent; daily dosing superior to bolus.

4. Curcumin (Turmeric)

Curcumin targets major CSC pathways (except JAK/STAT), exerts anti-inflammatory/antioxidant effects, induces apoptosis, and suppresses glycolysis/EMT. Over 50 trials (16/21 showing efficacy); preclinical/clinical transitions; synergizes in protocols like Joe Tippens. Recommended: 500 mg twice daily or 2-8g bioavailable/day with piperine. Caveats: Blood-thinning risks; poor absorption.

5. Berberine

Berberine destabilizes β-catenin (WNT), inhibits Notch1, PI3K/AKT, STAT3/JAK-STAT, and Hedgehog; suppresses EMT and stemness via TGF-β blockade; serves as a non-prescription alternative to metformin with superior effects in some CSC pathways. AI comparisons and studies show anti-cancer mechanisms, including STAT3 inhibition and modulation of cell signaling. Recommended: Dosage per Root Detox (typically 500-1500 mg/day) (7). Caveats: GI effects; interact with CYP3A4 inhibitors.

6. EGCG (Green Tea Extract)

EGCG blocks WNT, STAT3, NF-κB, Notch, PI3K/AKT; targets CSC self-renewal and reduces inflammation/immune surveillance. Preclinical evidence supports inhibition of CSC pathways and tumor progression. Recommended: 800 mg/day or equivalent 4 cups green tea. Caveats: Safe ≤800 mg/day; mild GI distress possible.

7. Vitamin C (High-Dose IV/Oral)

Vitamin C generates pro-oxidant reactive oxygen species (ROS), competes with glucose, induces CSC apoptosis, inhibits glycolysis/glutaminolysis, and polarizes macrophages. RCTs prolong survival; outperforms chemotherapy in vivo; deficiency linked to elevated HIF-1 in tumors. Seminal preclinical work demonstrates that vitamin C's anticancer activity is limited by up-regulation of stress-inducible heme-oxygenase-1 (HO-1) and ferritin in KRAS-mutant cells; FMD selectively reverses this, elevating reactive iron and ROS to induce near-complete cell death in KRAS-mutant models (e.g., colorectal, pancreatic, lung), sparing healthy cells and potentiating chemotherapy. Recommended: IV 50-75g 2-3x/week with chemotherapy; oral 2g with doxycycline or FMD for KRAS+ cases (many grams IV, caution for GI/kidney issues). Caveats: Antioxidant in prevention; avoid high oral doses during ROS-based therapies; confirm KRAS status.

8. Doxycycline + Vitamin C

This combination inhibits mitochondrial function/metastasis, blocks Wnt/Hedgehog/Notch, with minimal microbiome disruption. Synergistic antiproliferative effects; extends DFS (Disease-Free Survival) in METRICS study for glioblastoma. Recommended: Doxycycline 50-200 mg/day + 2g vitamin C; cycle after 6 months. Caveats: Core for brain tumors.

9. Hyperbaric Oxygen Therapy (HBOT)

HBOT reverses hypoxia, induces ROS/OxPhos, targets CSCs/metastases, and synergizes with metabolic strategies. Cochrane reviews confirm benefits in head/neck cancers; prolongs survival in metastatic models. Recommended: 2-3x/week. Caveats: Contraindicated with select chemotherapies; enhances efficacy.

10. Exercise & Stress Reduction + Intermittent Fasting

These improve OxPhos/mitochondrial volume, reduce inflammation/insulin, inhibit proliferation, activate AMPK/autophagy, and sensitize to chemo. Meta-analyses show HR=0.59 for breast mortality; ashwagandha reduces cortisol by 28%; fasting RCTs improve PFS. FMD (Fasting-Mimicking Diet) variant (5 days/month: Day 1 at 600 calories, Days 2-5 at 300 calories; plant-based, low-protein) synergizes with vitamin C for KRAS-mutants by downregulating HO-1/ferritin, amplifying oxidative stress. 
Recommended: 150 min/week moderate exercise; mindfulness/yoga; 16:8 fasting or FMD. 
Note: This may seem like a generic strategy, but the fight against cancer is a long-term battle. Small, practical changes can cumulatively make a significant impact on the final outcome.
Caveats: Counters cachexia; avoid in elderly/cachexia (severe weight loss)/pregnancy.Integrated ProtocolsHybrid orthomolecular protocols combine vitamin C/D/zinc, ivermectin/benzimidazoles/DON, fasting, exercise/HBOT over 12 weeks, monitoring GKI/blood levels. FLCCC/IMA approaches core ivermectin/mebendazole/doxycycline/curcumin, adding specifics (e.g., IV vitamin C for pancreatic; statins for breast); aggressive stage 4 regimens use 6-10 agents with metronomic chemotherapy. 
The Root Detox Protocol (Root3™ to Root10™) provides tiered regimens for CSC inhibition: Root3™ (EGCG/curcumin/vitamin D); Root4™ (+omega-3); Root5B™ (+berberine); Root9™ (+celecoxib/ivermectin/mebendazole); Root10™ (+exercise). Estimated risk reductions: 50-95% across cancers. (7)
For KRAS-mutants, integrate vitamin C + FMD (e.g., with FOLFOX or gemcitabine) per Di Tano et al., targeting HO-1/ferritin reversal for enhanced efficacy, pending trials. Perioperative strategies employ propranolol + COX-2 inhibitors + cimetidine to mitigate metastasis. Adjunctives include microbiome restoration (e.g., inulin prebiotics) and modalities like hyperthermia/TTFields/photodynamic therapy for synergy. (5)Evidence Analysis and Future DirectionsThe evidentiary landscape for metabolic interventions and repurposed drugs in cancer therapy is heterogeneous, reflecting the field's nascent stage. Strongest clinical support exists for established agents like metformin (or berberine as an alternative) and vitamin D, backed by multiple meta-analyses and RCTs demonstrating significant reductions in cancer risk and mortality (e.g., 45% thyroid risk reduction with metformin; 6-12% overall mortality drop with vitamin D/omega-3). 
For repurposed antiparasitics like ivermectin and benzimidazoles, evidence leans heavily on preclinical models and case series (>300 ivermectin cases showing NED in advanced cancers) (8), with emerging RCTs exploring synergies (e.g., ivermectin with pembrolizumab in metastatic triple-negative breast cancer, NCT-2022-02421). Preclinical data highlight ivermectin's induction of immunogenic cell death and T-cell infiltration, potentially enhancing immunotherapy, though human meta-analyses are lacking, and oncologists note widespread interest amid unproven claims. 
Vitamin C and doxycycline combinations show synergistic effects in glioblastoma via METRICS study extensions of DFS, while HBOT and exercise yield consistent benefits in meta-analyses for survival and quality of life. 
The Root Detox Protocol introduces AI-derived estimates (from PubMed preclinical data) of 50-95% risk reductions, emphasizing synergy in CSC pathway blockade, though requiring clinical validation. The Di Tano et al. study (2020) provides mechanistic depth to vitamin C + FMD synergies, showing FMD-mediated reversal of HO-1/ferritin up-regulation in KRAS-mutants, leading to iron/ROS overload and tumor regression in models—effects amplified by chemo but absent in non-KRAS contexts. 
Recent preclinical work on vitamin C + FMD (e.g., Di Tano et al., Nature 2020) demonstrates targeted efficacy in KRAS-mutants, supported by subgroup analyses in trials like Wang et al. (2022) for colorectal and Bodeker et al. (2024) for pancreatic, with an ongoing combo trial. However, overall, while preclinical synergies (e.g., metabolic stress sensitization) are promising, translation to large-scale human trials remains limited, with most data from observational or small-scale studies. Future directions include expanding Phase II/III trials, leveraging computational repurposing (e.g., AI-driven network pharmacology to identify synergies), and nanomaterials for targeted delivery to overcome bioavailability issues. International collaborations, such as ReDO and emerging U.S.-China initiatives, aim to accelerate off-patent drug testing, potentially integrating genomics for precision repurposing.Challenges of Metabolic InterventionsImplementing metabolic therapies faces multifaceted hurdles. Metabolic plasticity allows cancer cells to adapt pathways, fostering resistance similar to targeted therapies, necessitating combination approaches and robust biomarkers for monitoring (e.g., lactate levels, PET imaging). Since metabolism is ubiquitous, off-target effects pose risks, particularly in nutrient-stressed patients (e.g., cachexia), requiring careful patient selection and avoidance in vulnerable groups like the elderly. Integration with standard care demands oncology coordination to manage interactions (e.g., PPIs reducing chemotherapy efficacy) and ensure adherence to complex regimens. Regulatory and economic barriers hinder repurposing, with off-patent drugs lacking pharmaceutical incentives, leading to reliance on non-profits and patient-driven initiatives. High-fat diets, previously considered, may exacerbate risks via metastasis promotion; instead, prioritize plant-based, fiber-rich (>25g/day) nutrition, whole foods, sleep (>7h), and sun exposure for prevention. Misinformation, particularly around unproven agents, complicates patient education and trial recruitment. Protocols like Root Detox highlight adherence challenges in multi-agent regimens.Conclusion and Future PerspectivesMetabolic interventions and repurposed drugs represent a paradigm shift in oncology, harnessing the MSCC and TME modulation to complement standard therapies and address unmet needs in advanced cancers. By targeting core vulnerabilities like glycolysis and CSC renewal, these approaches offer accessible, low-toxicity adjuncts, with agents like ivermectin and metformin (or berberine) showing preliminary synergies in enhancing immunotherapy and reducing relapse. The Root Detox Protocol exemplifies integrated prevention, with AI-estimated high risk reductions underscoring the potential of synergistic CSC targeting, though preclinical-heavy evidence calls for robust trials. Innovations like vitamin C + FMD for KRAS-mutants, as detailed in Di Tano et al., further personalize metabolic strategies by exploiting mutation-specific stress responses, bridging preclinical promise to clinical application. However, the field must navigate evidentiary gaps, prioritizing rigorous RCTs to validate preclinical promise and dispel myths. Future perspectives are optimistic, with drug repurposing accelerating through AI, big data, and global equity initiatives to make off-patent therapies universally available, potentially transforming cancer care in resource-limited settings. 

References:

1. https://www.nature.com/articles/s41392-024-01808-1 (2024)
2. https://imahealth.org/wp-content/uploads/2023/06/Cancer-Care-FLCCC-Dr-Paul-Marik-v2.pdf
3. https://imahealth.org/wp-content/uploads/2025/02/approach-to-repurposed-drugs-for-cancer.pdf
4. https://isom.ca/article/targeting-the-mitochondrial-stem-cell-connection-in-cancer-treatment-a-hybrid-orthomolecular-protocol/
5. https://www.nature.com/articles/s41467-020-16243-3 (2020)
6. Top 20 Alternative Cancer Treatments that Work: Evidence Based (2025 Edition)
7. Root Detox Protocol: The Optimal Cancer Risk Reduction Protocol to reduce Risk by 95%? - Dr Justus Hope
8. Fenbendazole Cancer Success Stories: 377 Case Reports Compilation (November 2025 Edition) - One Day MD